For example, targeting receptors that are overexpressed in specific cancers, such as HER2 in breast cancer, enables direct delivery of chemotherapeutic agents to malignant cells while minimizing systemic toxicity (Krishnamurti and Silverman, 2014; Ratajczak et al., 2023). This evidence concerns the gene ERBB2 and cancer.